Articles By Rachel Tate, DO
PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?
By Rachel Tate, DO
17 June 2022
POS0309 at EULAR 2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies.
Read Article
Complementary and Alternative Therapies in Psoriasis and Psoriatic Arthritis
By Rachel Tate, DO
14 April 2022
It’s been reported that approximately one-third to one-half of patients with psoriatic arthritis will try supplements and other complementary and alternative medicinal (CAM) practices without discussing with their rheumatologists. Of those, nearly 90% of PsA patients using CAM report benefits! Here is your updated review on common supplement data in psoriasis and PsA.
Read Article
MDA: Aiming for Perfection in PsA
By Rachel Tate, DO
07 April 2022
When it comes to psoriatic arthritis clinical trials such as TICOPA (tight control in PsA) have consistently shown that treating to target correlates with improved disease domain and patient reported outcomes. Minimal disease activity (MDA) has become an oft used target and outcome in PsA trials. While many of us measure and record a variety of measures in our patient charts, we may be on our way to demonstrating MDA in practice. Here is a quick review of MDA components and how to capture them for your patients.
Read Article
Sick Leave in axSpA: Who takes more?
By Rachel Tate, DO
07 November 2021
Who wouldn't like to predict the future?
Read Article
Polyautoimmunity: axSpA and Familial Mediterranean Fever
By Rachel Tate, DO
05 November 2021
Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA), remains rare. In fact, we believe the rate to be between 0.5% and 7.5%.
Read Article
Three Healthcare Hashtags You Should Follow
By Rachel Tate, DO
14 September 2021
I've sent more than 2,000 tweets since joining Twitter in July 2010. Even better, I've read (and sometimes shared) thousands of other educational, informative and sometimes humorous tweets from fellow rheumatologists, physicians, healthcare providers and others around the world. While following individuals and organizations relevant to you is important, so is following hashtags. Here are three I recommend.
Read Article
ICYMI: New GRAPPA 2021 PsO and PsA Treatment Recommendations
By Rachel Tate, DO
07 July 2021
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr. Laura Coates, Oxford detailed in abstract #OP0229. Since the last update in 2015, there have been multiple changes, which are highlighted here.
Read Article
Q-DAPSA for Measuring Disease Activity in PsA
By Rachel Tate, DO
10 June 2021
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.
Read ArticleNew GRAPPA 2021 PsO and PsA Treatment Recommendations
By Rachel Tate, DO
04 June 2021
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read Article
HLA B27 Iritis - RNL 2021 Highlights
By Rachel Tate, DO
31 March 2021
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
Read Article